Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in EuropeBusiness Wire • 09/24/20
Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%Business Wire • 09/15/20
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/09/20
Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business UpdateBusiness Wire • 08/06/20
Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020Business Wire • 07/30/20
Will Aerie Pharmaceuticals (AERI) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/29/20
Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein OcclusionBusiness Wire • 07/27/20
Aerie (AERI) Up 1.9% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/05/20
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/08/20
Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/06/20
Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 04/28/20
So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be PrematureThe Motley Fool • 04/01/20
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/21/20
Aerie (AERI) Up 4.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/06/19